Search | TVST | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 14 of 14

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2023

Novel YP-P10 Peptide reduces corneal damage in a mouse dry eye model compared with Lifitegrast, Cyclosporine, Diquafosol sodium and Hyaluronic acid.

Laxmikant Gharat; Larry Park; Kyungho Park; Hyun Woo Park; Gary D Novack

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):699.

ARVO Annual Meeting Abstract June 2022

Two Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Studies of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution 8% (AG-920)

Victor H Gonzalez; Gary D Novack; David Wirta; Martin Uram; Audrey Schupp; Michelle C Widmann

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):334 – F0165.

ARVO Annual Meeting Abstract June 2022

Evaluation of novel YP-P10 Peptide in animal models of inflammatory dry eye disease

Larry Chong Park; Laxmikant Gharat; Kyungho Park; Jahan Alam; Zhiyuan Yu; Yelin Hu; Cintia S De Paiva; Gary D Novack; Stephen C Pflugfelder

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1984 – A0314.

ARVO Annual Meeting Abstract June 2021

Nonclinical Development of AG-920, A Topical Ocular Anesthetic for Analgesia During Intravitreal Injection

Rozemarijn S Verhoeven; Martin Uram; Audrey Schupp; Gary D Novack

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):716.

ARVO Annual Meeting Abstract June 2017

The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in Humans

Arthur J Sit; Arash Kazemi; Jay W McLaren; Casey Kopczynski; Theresa G H Heah; Gary D Novack

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2112.

ARVO Annual Meeting Abstract June 2017

Evaluation of the XEN45 Gel Stent in Patients with Primary Angle Closure Glaucoma

Francisco Millan; Maria E. Reveron; Lilian Gonzalez; Miguel Siso; Carelys Suescum; Gary D Novack; Susan S Lee; Vanessa Vera

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2113.

ARVO Annual Meeting Abstract June 2017

A double-masked, randomized, parallel study of Netarsudil Ophthalmic Solution, 0.02% QD compared to timolol maleate ophthalmic solution, 0.5% BID in patients with elevated intraocular pressure (ROCKET-4)

Albert S Khouri; Theresa Heah; Casey Kopczynski; Gary D Novack

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2461.

ARVO Annual Meeting Abstract September 2016

Two Phase 3 studies of the efficacy and safety of AR-13324 Ophthalmic Solution 0.02%: in Patients with Open Angle Glaucoma and Ocular Hypertension

L Jay Katz; Mark J. Weiss; Theresa Heah; Casey Kopczynski; Gary D Novack

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract June 2015

Fixed dose combination of AR-13324 and latanoprost (PG324): A double-masked, randomized, controlled study in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Harvey Dubiner; Brian Levy; Nancy Ramirez; Casey Kopczynski; Gary D Novack; PG324-CS201

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5704.

ARVO Annual Meeting Abstract April 2014

Double-masked, randomized, dose-response study of AR-13324 Ophthalmic Solution compared to latanoprost in patients with elevated intraocular pressure

Harvey Dubiner; Brian Levy; Casey Kopczynski; Gary D Novack

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):545.

Perspective September 2013

Translating Drugs From Animals to Humans: Do We Need to Prove Efficacy?

PDF

Gary D. Novack
TAGS: translating
Trans. Vis. Sci. Tech.. 2013; 2(6):1. https://doi.org/10.1167/tvst.2.6.1

ARVO Annual Meeting Abstract April 2011

A 28-day Active-controlled, Phase 2b Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients with Elevated Intraocular Pressure

Janet B. Serle; Gary D. Novack; Thomas J. Van Haarlem; Casey Kopczynski; AR-12286 Phase 2b Study Group

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):217.

ARVO Annual Meeting Abstract April 2011

Ocular Hypotensive Efficacy, Safety, and Systemic Absorption of AR-12286 in Normal Volunteers

Casey Kopczynski; Gary D. Novack; Dennis Swearingen; Thomas J. Van Haarlem

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6689.

Editorial November 1999

ARVO Commercial Relationships Policy: Financial Disclosure in ARVO Presentations and Publications

PDF

Gary D. Novack
TAGS: disclosure
Invest. Ophthalmol. Vis. Sci.. 1999; 40(12):2765-2766.

Advertisement